"A phase II open-label study in adult and adolescent patients (pts) with advanced solid tumors harboring fibroblast growth factor receptor (FGFR) gene alterations."

LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

TPS480Background: The pan-FGFR tyrosine kinase inhibitor erdafitinib is approved by the US Food and Drug Administration for adults with locally advanced or metastatic urothelial carcinoma and susce... Click to show full abstract

Keywords: adult adolescent; label study; phase open; adolescent patients; study adult; open label

Journal Title: Journal of Clinical Oncology
Year Published: 2021

Link to full text (if available)

Share on Social Media: Sign Up to like & get
recommendations!
1

LAUSR

You are not signed in:

Sign Up!

Related content

More Information News Social Media Video Recommended